Sells life science research instruments, software and consumables to pharmaceutical and biotechnology companies, laboratories and contract research organizations.
10-K for FY2025, filed Mar 13, 2026Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services…View ↗
Our products, consumables, software and services enable fundamental advances in life science applications, including research…View ↗
We have organized our product line activities into two product families, Cellular and Molecular (“CMT”) and Preclinical. Our CMT product…View ↗
Customers generally place purchase orders for instruments, equipment and accessories, which are typically paid for when the products ship. They pay separately for services when performed and for maintenance and warranty contracts over the service period.
10-K for FY2025, filed Mar 13, 2026The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase…View ↗
Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of…View ↗
Service revenue consists of installation, training, data analysis and surgeries performed on research animals. Service revenue is…View ↗
The Company’s payment terms are generally from zero to sixty days from the time of invoicing, which occurs at the time of shipment or prior…View ↗
10-K for FY2025, filed Mar 13, 2026
FY2025 revenue by product or service ↗$86.6M
10-K for FY2025, filed Mar 13, 2026
$86.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Instruments, Equipment, Software, and Accessories
Sold outright
10-K for FY2025, filed Mar 13, 2026 |
90%
FY2022: 95%
|
Instruments, Equipment, Software, and Accessories, FY2025
$78.3M Sources
|
Sold outright |
|
Service, Maintenance, and Warranty Contracts
|
9.6%
FY2022: 4.6%
|
Service, Maintenance, and Warranty Contracts, FY2025
$8.3M Sources
|
Sales reach end users through direct sales and distributors in the United States, China and major European markets; original equipment makers also incorporate products into offerings under their own brands.
10-K for FY2025, filed Mar 13, 2026Our end-user customers are primarily pharmaceutical and biotechnology companies, universities, hospitals, government laboratories…View ↗
We conduct direct sales and sales through distributors in the United States, China and major European markets. We engage distributors for…View ↗
The Company’s customers are primarily research scientists at pharmaceutical and biotechnology companies, universities, hospitals…View ↗
Not on paper. It lost $56.7M in FY2025, but brought in more cash than it spent: $5.5M of free cash flow.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$2.6MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
Shrinking. Revenue fell 27% in 4 years, from $118.9M in FY2021 to $86.6M in FY2025, about 8% a year.
More focus on organoid research
The latest report describes products for organoid research, including MeshMEA, and a strategy to build offerings across in vivo and in vitro research. The older report described the product families and research uses without this organoid-focused strategy.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 13, 2026We have organized our product line activities into two product families, CMT and Preclinical.View ↗
Our CMT product family is primarily composed of products supporting research related to molecular, cellular organ and organoid…View ↗
Our Preclinical product family includes four business lines that support the preclinical research and testing phase for drug development…View ↗
As the life sciences industry accelerates toward New Approach Methodologies (“NAMs”), Harvard Bioscience expects to evolve from a…View ↗
Leading the Translational Bridge: bridging in vivo and in vitro research by leveraging the Company’s strong preclinical position to…View ↗
precision scientific measuring instrumentation and equipment in the field of electrophysiology such as: data acquisition systems with…View ↗
Consumables and software
The latest report describes a strategy to shift toward consumables and software and increase recurring revenue. The older report described products augmented with consumables, software and services, but did not describe that strategic focus.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 13, 2026Our solutions range from simple to complex, and generally consist of hardware/firmware and software products, augmented with consumables…View ↗
Consumables Revenue Expansion: shifting mix toward higher-margin consumables and software with a path to increasing recurring revenue from…View ↗
Competes with Agilent, Becton, Dickinson and, Bio-Rad Laboratories, Danaher, Emka Technologies, Eppendorf, Hitachi, Instem, Kent Scientific, Lonza Group, Revvity, Thermo Fisher Scientific, TSE Systems, and Waters
10-K for FY2025, filed Mar 13, 2026We compete with several companies that provide products for life science research including Agilent, Becton, Dickinson and Company, Bio-Rad…View ↗
Loading...